Phenomix Sciences is at the forefront of precision medicine in obesity treatment, utilizing its innovative MyPhenome™ test to analyze an individual's DNA and predict their response to various weight loss interventions. This test categorizes obesity into four distinct phenotypes—Hungry Brain, Hungry Gut, Emotional Hunger, and Slow Burn—allowing healthcare providers to tailor treatment plans based on the specific biological and psychological traits associated with each phenotype. Research led by prominent physicians from the Mayo Clinic has demonstrated that this approach can significantly enhance weight loss outcomes, effectively doubling the number of treatment responders and the amount of weight lost when interventions are aligned with a patient's phenotype.

The company emphasizes the importance of data-driven medicine in managing obesity, as DNA is believed to contribute 40-70% to body composition. By integrating behavioral and biomarker data, Phenomix's MyPhenome™ test provides actionable insights that empower both patients and healthcare professionals to make informed decisions regarding obesity treatment. This personalized approach not only streamlines the selection of anti-obesity medications but also aims to reduce the trial-and-error nature of current treatment methods, ultimately leading to more effective and efficient weight management strategies.

United States

Phenomix Sciences is a precision medicine obesity biotechnology company on a mission to conquer obesity globally through the use of proprietary testing and personalized lifestyle guidance. The company offers the MyPhenome™ test, exclusively licensed from Mayo Clinic, which measures DNA and metabolites related to obesity to improve weight-loss effectiveness. Phenomix Sciences is committed to advancing the understanding of obesity treatment through precision medicine and believes in the power of knowledge and accurate diagnosis.

Phenomix Sciences

Company Details